Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOR NASDAQ:BCDA NASDAQ:BVXV OTCMKTS:ENZN NASDAQ:LIFE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCDABioCardia$1.17-23.8%$2.02$1.00▼$3.25$8.92M0.85101,018 shs19.91 million shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsENZNEnzon Pharmaceuticals$0.07+2.8%$0.08$0.06▼$0.24$5.38M0.3516,438 shs6,055 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%BCDABioCardia-23.78%-48.46%-37.43%-43.75%-62.01%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ENZNEnzon Pharmaceuticals-3.62%-4.49%-5.93%-8.02%-43.69%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCDABioCardia$1.17-23.8%$2.02$1.00▼$3.25$8.92M0.85101,018 shs19.91 million shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsENZNEnzon Pharmaceuticals$0.07+2.8%$0.08$0.06▼$0.24$5.38M0.3516,438 shs6,055 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%BCDABioCardia-23.78%-48.46%-37.43%-43.75%-62.01%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ENZNEnzon Pharmaceuticals-3.62%-4.49%-5.93%-8.02%-43.69%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda Therapeutics 0.00N/AN/AN/ABCDABioCardia 3.50Strong Buy$25.002,036.75% UpsideBVXVBiondVax Pharmaceuticals 0.00N/AN/AN/AENZNEnzon Pharmaceuticals 0.00N/AN/AN/ALIFEaTyr Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00BCDABioCardia$60K113.30N/AN/A$0.18 per share6.50BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/AENZNEnzon Pharmaceuticals$30K184.29$0.01 per share6.92$0.04 per share1.86LIFEaTyr Pharma$350K0.00N/AN/A$1.54 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/ABCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/12/2025 (Estimated)BVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/AENZNEnzon Pharmaceuticals$780K-$0.03N/A∞N/AN/A-91.38%-4.03%11/3/2025 (Estimated)LIFEaTyr Pharma-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%N/ALatest ENZN, LIFE, BVXV, ACOR, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ENZNEnzon PharmaceuticalsN/A-$0.02N/A-$0.02N/AN/A8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26BCDABioCardiaN/A0.330.33BVXVBiondVax PharmaceuticalsN/A4.124.12ENZNEnzon PharmaceuticalsN/A55.7155.71LIFEaTyr Pharma0.026.076.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%BCDABioCardia20.57%BVXVBiondVax Pharmaceuticals11.83%ENZNEnzon PharmaceuticalsN/ALIFEaTyr Pharma61.72%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%BCDABioCardia20.00%BVXVBiondVax Pharmaceuticals6.03%ENZNEnzon Pharmaceuticals0.40%LIFEaTyr Pharma3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataBCDABioCardia405.81 million4.64 millionOptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableENZNEnzon PharmaceuticalsN/A74.21 million73.92 millionNot OptionableLIFEaTyr Pharma5669.01 million66.46 millionOptionableENZN, LIFE, BVXV, ACOR, and BCDA HeadlinesRecent News About These CompaniesLake Victoria Gold Announces Closing of Oversubscribed Non-Brokered LIFE Private Placement of Units for $6 Million and Upsize of Concurrent Private Placement to $2 MillionSeptember 17 at 7:01 AM | newsfilecorp.comNSilver Dollar Announces $4.0 Million Brokered LIFE OfferingSeptember 16 at 7:00 PM | newsfilecorp.comNPTX Metals Inc. Announces Private Placement AmendmentsSeptember 16 at 5:03 PM | newsfilecorp.comNSilver47 Announces Closing of $23 Million Brokered LIFE Financing, Including Full Exercise of the Over-Allotment OptionSeptember 16 at 1:09 PM | newsfilecorp.comNaTyr Pharma's Phase 3 EFZO-FIT Study Results: A New Hope for Pulmonary Sarcoidosis TreatmentSeptember 15, 2025 | sohu.comSInvesting in aTyr Pharma: Weighing the Risks and Rewards of a Promising BiotechSeptember 15, 2025 | sohu.comSATyr shares plunge on trial miss in inflammatory lung diseaseSeptember 15, 2025 | biopharmadive.comBNord Precious Metals Announces Non-Brokered LIFE FinancingSeptember 15, 2025 | thenewswire.comTaTyr flunks phase 3 lung disease trial, deflating stock, but still plans talks with FDASeptember 15, 2025 | fiercebiotech.comFHayasa Announces Upsizing of Private Placement LIFE Offering of Units to C$2M from C$1.7MSeptember 15, 2025 | newsfilecorp.comNaTyr Pharma Reports Phase 3 EFZO-FIT™ Study Results for Efzofitimod in Pulmonary Sarcoidosis, Highlighting Clinical Improvements Despite Primary Endpoint Not MetSeptember 15, 2025 | quiverquant.comQF3 Announces Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$17 MillionSeptember 11, 2025 | newsfilecorp.comNF3 Announces Bought Deal LIFE Private Placement for Gross Proceeds of C$15 MillionSeptember 10, 2025 | newsfilecorp.comNHayasa Announces Non-Brokered LIFE Offering of UnitsSeptember 9, 2025 | newsfilecorp.comNESGold Announces Upsize of Brokered LIFE Offering for Gross Proceeds of up to C$6.5 MillionSeptember 8, 2025 | newsfilecorp.comNFuture Fuels Announces $2.25 Million LIFE Flow-Through OfferingSeptember 5, 2025 | accessnewswire.comAESGold Announces Brokered LIFE Offering for Gross Proceeds of up to C$5 MillionSeptember 5, 2025 | newsfilecorp.comNEloro Resources Announces Further Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$11.0 MillionAugust 27, 2025 | globenewswire.com2 Small-Cap Biotech Stocks Well Positioned for a BreakoutAugust 27, 2025 | fool.comSilver47 Announces Upsize of Brokered LIFE Financing to $20 MillionAugust 26, 2025 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMongoDB Roars Back to Life: It’s Not Too Late to Buy MoreBy Thomas Hughes | August 27, 20252 Reasons to Scoop Up Rubrik Stock and Hold on for LifeBy Thomas Hughes | September 11, 2025GameStop Returns to Growth, Don’t Expect Another Meme SpikeBy Thomas Hughes | September 11, 2025Biotech Sector May Flip to Market Leader by Year-EndBy Ryan Hasson | September 15, 20255 Clean Energy Stocks Poised for the Next Green RallyBy Ryan Hasson | September 8, 2025ENZN, LIFE, BVXV, ACOR, and BCDA Company DescriptionsAcorda Therapeutics NASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.BioCardia NASDAQ:BCDA$1.17 -0.37 (-23.78%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$1.15 -0.02 (-1.71%) As of 09/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.BiondVax Pharmaceuticals NASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Enzon Pharmaceuticals OTCMKTS:ENZN$0.07 +0.00 (+2.76%) As of 09/18/2025 02:55 PM EasternEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.aTyr Pharma NASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
